drugset / Trial / NCT02920918
Treatment of Diabetes in Patients With Systolic Heart Failure
Phase 4
Completed
36 enrolled
Virginia Commonwealth University
Janssen Scientific Affairs, LLC · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Investigator Initiated Study to study the effects of Canagliflozin 100 milligrams (mg) vs Sitagliptin 100 mg on parameters of aerobic exercise capacity (peak oxygen consumption \[VO2\]) and ventilator efficiency (minute ventilation \[VE\]/carbon dioxide production \[VCO2\] slope) at cardiopulmonary exercise test (CPET) after 12 weeks of active treatment (primary endpoints). Blood pressure (BP), body water content, body composition, cardiac function, and diet will be also measured (secondary endpoints).
Timeline
- Start
- 2016-10
- Primary completion
- 2018-09
- Completion
- 2018-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CANAGLIFLOZIN ANHYDROUS | Small molecule | 100 mg | Oral |
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |